Drug Trial Radar · NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
686
Planned (sponsor's estimate)
Start
Oct 24, 2025
Primary completion
Apr 24, 2030
Study completion Nov 24, 2032
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Conditions
- Non-small Cell Lung Cancer
Interventions
Trastuzumab DeruxtecanDrug
T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
pembrolizumabDrug
pembrolizumab will be administered at a dose of 200 mg IV Q3W
PemetrexedDrug
Pemetrexed will be administered at a dose of 500 mg/m\^2 IV Q3W
Platinum ChemotherapyDrug
One of the following two will be administered in Arm B: Cisplatin at a dose of 75 mg/m\^2 IV or carboplatin AUC at a dose of 5 mg/mL/min IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival by Blinded Independent Central ReviewTime frame: From date of randomization to the date of radiographic disease progression or death due to any cause, up to approximately 54 months
Locations
247 sites in 24 countries. Site status is shown where the registry gives one.
Alaska Oncology & Hematology, LLC
Anchorage, Alaska · Recruiting
Orange Coast Memorial Medical Center Fountain Valley
Fountain Valley, California · Recruiting
California Research Institute
Los Angeles, California · Recruiting
Los Angeles Cancer Network (LACN)
Los Angeles, California · Recruiting
Providence Medical Foundation
Santa Rosa, California · Recruiting
Bay Pines VA Healthcare System
Bay Pines, Florida · Recruiting
Lynn Cancer Institute Center
Boca Raton, Florida · Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida · Recruiting
Mid-Florida Hematology & Oncology Centers, P.A.
Orange City, Florida · Recruiting
BRCR Global Plantation
Plantation, Florida · Recruiting
Cleveland Clinic Florida - Weston
Weston, Florida · Recruiting
Piedmont Cancer Institute OneOncology
Atlanta, Georgia · Recruiting
The Queens Medical Center
Honolulu, Hawaii · Recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Logan Health Research
Kalispell, Montana · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
Clinical Research Alliance
Westbury, New York · Recruiting
FirstHealth Cancer Center
Pinehurst, North Carolina · Recruiting
Carolina Cancer Research Center
Wilson, North Carolina · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
St. Charles Health System
Bend, Oregon · Recruiting
University of Texas M. D. Anderson Cancer Center
Houston, Texas · Recruiting
Lumi Research
Kingwood, Texas · Recruiting
Summit Cancer Treatment Center
Spokane, Washington · Recruiting
CINME - Centro De Investigaciones Metabolicas
Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina · Recruiting
Instituto Argentino de Diagnostico y Tratamiento
Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Metabolicas (IDIM)
Buenos Aires, Argentina · Recruiting
Centro de Investigaciones Medicas y Desarrollo LC SRL (LC Investigacion)
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clinicas Cordoba S.A.
Córdoba, Argentina · Recruiting
Centro de Investigacion Pergamino SA
Pergamino, Argentina · Recruiting
Hospital Universitario Austral
Pilar, Argentina · Recruiting
Sanatorio Britanico S.A.
Rosario, Argentina · Recruiting
Instituto de Oncologia de Rosario
Rosario, Argentina · Recruiting
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, Argentina · Recruiting
Sanatorio Parque S.A.
Rosario, Argentina · Recruiting
Instituto San Marcos
San Juan, Argentina · Recruiting
UZA
Edegem, Belgium · Recruiting
Showing 40 of 247 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.